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Brief Overview 
The most recent AIDS statistics 
have put the epidemic into chilling 
perspective. HIV infection is now the 
second leading cause of death in young 
men in the United States. HIV is the 3rd 
leading cause of mortality in young 
minority women, more deadly than 
suicide and homicide. 
In the second decade of the 
AIDS epidemic the new cases of AIDS 
reported in 1992 among women have 
increased 9.8%, compared to 2.5% for 
men. .For the first time, more women 
were infected through sexual contact than 
I.V. drug use . 
The greatest growth in new cases 
has been among minority women, who 
make up 19,544 of the 36,690 cases of 
AIDS reported through June 1993. Only 
cancer and heart disease outrank HIV 
infection in mortality of young black 
women, whereas AIDS is the ninth 
leading cause of death in white women. 
Newest CDC data confirms that 
the epidemic is spreading most rapidly 
among teens, especially girls. In 1993, 
15% of U.S. cases of AIDS were women. 
Maine statistics for June 1994 show that 
8% of recently reported AIDS cases were 
women. 
Diagnosis of HIV in Women 
The natural history of HIV 
disease is similar in men and women. A 
primary HIV syndrome ("flu-like" , 
"mono-like") may occur within 1-2 
months of infection, to be followed by an 
asymptomatic phase that usually persists 
for years. As in men, early symptoms of 
immune decline may include 
dermatologic disease (worsening 
seborrheic dermatitis, psoriasis, warts, 
shingles, etc .) and, later on, thrush . In 
addition, women with HIV may develop 
chronic or recurrent monilial vaginitis. 
Herpes genitalis and pelvic inflammatory 
disease may become protracted and 
HIV in Women 
difficult to treat. Unlike men, Kaposi's 
sarcoma, however, has rarely been 
reported in women. 
To diagnose HIV in women, 
physicians should include a sexual history 
as part of their medical evaluation, be 
alert to HIV -related symptoms, and be 
able to facilitate HIV testing when 
appropriate . 
Management of HIV Disease in Women 
Although most studies of HIV 
disease and its treatment were based on 
men, recent work suggests a similar 
disease course and treatment response in 
men and women. One very important 
observation in women with HIV is the 
increased incidence of cervical dysplasia 
and carcinoma. Up to 50% of women 
with HIV disease may have cervical 
dysplasia, with the highest rates occurring 
in women with lower CD4 counts. PAP 
tests are recommended on an every 6 
month basis in women with later stages 
of HIV. Although the sensitivity of PAP 
tests for dysplasia in women with HIV 
has been questioned, a report at the recent 
Yokohama International Conference 
showed similar sensitivity of colposcopy 
and PAP screening. However, when PAP 
tests are abnormal, colposcopy should be 
done to further evaluate the condition, 
and may be necessary for subsequent 
follow-up. Despite the high evidence of 
dysplasia , invasive cervical carcinoma is 
rare. 
Prevention 
Routine examination offers an 
important opportunity for discussion of 
sexually transmitted diseases and their 
prevention. The value of barrier 
contraceptives and topical spermicides in 
the prevention of herpes, chlamydia, and 
HIV should be reinforced in women who 
are at risk. 
FaCC 1994 
Mother to Child 
Transmission of HIV 
Decreased by AZT 
Treatment 
Transmission of HIV infection 
from an HIV infected woman to her child 
may occur in utero , during delivery , or 
during postpartum breast feeding. 
Previous studies have revealed a range of 
transmission risk (10% to 40%), with the 
highest risk occurring in women with late 
stage HIV disease , or in developing 
countries. 
The results of a new study 
(ACTG 076) of the effect of AZT on 
vertical transmission of HIV were 
recently released. This study 
demonstrated a 2/3 reduction in mother to 
child transmission of HIV in the AZT 
treated cohort. This study included 
women 14 - 34 weeks pregnant who had 
not previously been treated with AZT. 
The protocol involved AZT treatment of 
the mother (500mg/d) until labor, then 
initiation of IV AZT (2mg kg} until 
childbirth. Following this, infants were 
treated with AZT for 6 weeks . No 
adverse effects of this regimen were 
noted in pregnant women or in their 
babies, with the exception of a transient 
anemia. 
As a result of this study, the 
FDA approved the use of AZT in HIV 
positive pregnant women. Additionally, 
the U.S . Public Health Service issued 
guidelines (see insert) that incorponte the 
uncertainties regarding the effectiveness 
of these treatments when women have 
later disease, prior history of AZT use , or 




Summary of National 
Trials Specific To 
women 
Natural History Trials 
A large scale study of the natural 
history of HIV disease in women. funded 
by the federal Centers for Disease Control 
and Prevention in Atlanta, and called the 
HIV Epidemiology Research Study 
(HERS), is being conducted at 4 sites 
across the country. Now in its first year 
of accepting patients, the 5 year study is 
enrolling a diverse group of 200 HIV-
positive women and 100 high-risk women 
at each site. Most of the HIV-positive 
women will be asymptomatic and have 
CD4 counts above 200. 
A companion study, called the 
Women's Interagency HIV Study (WIHS), 
is being sponsored by the National 
Institute of Allergy and Infectious 
Diseases in Bethesda, MD. Like HERS, 
WIHS will focus on identifying clinical 
signs of HIV in women. 
Both studies will try to identify 
factors that affect the progression of the 
disease in women. They will focus on 
gynecological issues, but also measure 
survival, psycho-social issues, access to 
health care, and quality of life. 
Other Significant Studies: 
Begun in 1990 the Heterosexual 
AIDS Transmission Study (HATS), has 
investigated risk factors tied to 
heterosexual transmission of HIV in 
women, particularly the unexplained 
higher risk among female cocaine users. 
Preliminary analysis has shown 
that female cocaine users have similar 
knowledge and behaviors toward HIV as 
non-cocaine users. The difference is that 
cocaine users have more sexual partners 
and more cases of other co-existing 
STDs. 
An NIAID-supported study is 
comparing women's diagnosis and 
survival compared to men's. Findings 
indicate that women whose infections are 
detected early survive as long as men and 
respond to treatment similar to men. 
Two studies within the AIDS 
Clinical Trials Group are looking at 
incidence of cervical dysplasia in women. 
The focus of one of the studies is 
comparing vaginal 5 Fluorouracil (5-FU) 
therapy to standard therapy for preventing 
recurrence of cervical dysplasia. 
The Women and Infants 
Transmission Study (WITS), begun in 
1989, continues to look at the natural 
history of HIV in pregnant women. A 
second study on women and infants is 
underway at the University of Medicine 
and Dentistry in New Jersey, and includes 
the effects of illegal drugs on pregnancies 
in HIV - positive women. 
Two early clinical trials 
sponsored by NIAID are enrolling women 
of childbearing age for two experimental 
vaccines. A third candidate vaccine trial 
is planned for pregnant women this fall. 
News Briefs from 
Yokohama 
In addition to the new 
information on the benefits of AZT use in 
seropositive pregnant women, the 
following observations from the I 0th 
International Conference on AIDS may be 
of particular interest to clinicians: 
I . Acyclovir appears to have a role as 
adjunctive therapy in HIV disease. 
Replication of Herpes viruses (HSV, 
CMV, EBV, etc.) may activate co-
existing HIV infection. Therefore, 
acyclovir, which inhibits replication of 
some herpes viruses, might be expected 
to have an indirect impact on HIV 
disease in these patients. Previous studies 
have suggested that the adjunctive use of 
high dose acyclovir (3-4 g/day) with AZT 
improves CD4 cell counts and/or survival 
in HIV infected persons. The 
results of the Multicenter AIDS 
Cohort Trial were presented in 
Japan. This large observational 
study demonstrated a survival 
benefit in patients receiving daily 
acyclovir (600-800 mg/day) in 
addition of AZT. The benefit was 
not limited to patients with a 
history of active herpes infections, 
though the vast majority of patients 
in this study were likely to be 
infected with HSV or CMV. The 
benefit of acyclovir was most 
apparent in patients with lower 
CD4 counts or AIDS defining 
illness. Although these studies are 
not conclusive, many clinicians are 
now adding acyclovir (600-800 
mg/d) to other treatment regimens 
in HIV infected patients with later 
stages of disease. 
2. New Measures of Viral Load 
(PCR for HIV RNA • . branched 
DNA tests) Have Predictive Value 
in Determining the Course of HIV. 
Evidence continues to mount that 
measures of viral load may predict the 
clinical course of HIV. New sensitive 
techniques that measure viral DNA or 
RNA in serum or peripheral blood cells 
may prove useful in determining 
responses to anti-retroviral agents, 
allowing clinicians to monitor course and 
adjust therapy. Although these 
techniques are not in routine use, 
preliminary studies suggest that they may 
play a major role in the near future. 
3. Combinations of Antiretroviral 
Therapy Show Promise. Although the 
results of several large trials of 
combination anti-retroviral therapy are 
not yet available, combination regimens 
continue to show promise in pilot studies. 
The addition of protease inhibitors, 
which prevent viral assembly in HIV -
infected cells, may be beneficial, 
particularly when used in combination 
with reverse transcriptase inhibitors. 
Several protease inhibitors are now 
entering phase III trials. 
4. Oral Gancyclovir Effective for 
Prevention of and Suppression of CMV 
Retinitis and Gastrointestinal mucosa! 
Disease. Although not yet released by 
the FDA, oral gancyclovir may prevent 
50% of cases of CMV retinitis, and can 
be effective in long term treatment of 
CMV retinitis. 
Active Treatment Arm of ACTG 076 
Prepartum (mother) 
Labor/Delivery (mother) 
Zidovudine 100 mg po sx day 
Zidovudine IV loading dose 2 mg/kg; continuous infusion 
1 mg1kg1hour 
Postpartum (infant) Zidovudine syrup 2 mg/kg po 4x day for 6 weeks. 
Management of GYN Infections in HIV+ Women 
Reference Used: The Sanford Guide to HIV/AIDS Therapy July 1993-1994 
Problem 
Vulvovaginal Candidiasis I Yeast Infection: 
May be the I st symptom of HIV infection in women, 1/3 of 
women with HIV develop chronic genital yeast infections. 
Causes severe itching & burning, odor, and "cheesy" discharge. 
Human Papillomavirus (HPV) 
Associated with the development of anogenital warts which may 
cause obstruction, abnormal pap smears, warts on the cervix , and 
possibly cancer-causing tissue growth; strongly associated with 
genital dysplasia . Cervical warts should not be treated until 
results of pap smear are known; avoid treating pregnant women. 
Pelvic Inflammatory DiseaseJPim 
Possibly caused by sexually transmitted organisms and though to 
be associated with chlamydia, with pelvic inflammation of the 
upper genital tract; also common are collections of pus in the 
fallopian tube or ovary . More common and more serious in 
women with HIV. 
Herpes Simplex Virus (HSV) 
Chronic lesions on vulvar or vaginal walls 
Treatment 
Topical (Vaginal): 
a. Miconazole nitrate 200 mg vag. tabs (I qd hs x 3 days) or 
2% cream (5gm) qd hs x7 days 
b. Clotrimazole 100 mg vag. tabs(2 qd hs x 3 days) or 
I% cream (5 gm) qd hs x 7 days 
Oral 
a. Fluconazole 150 mg p.o. qd. x3 days (Not an FDA -approved 
indication) 
b. Itraconazole 200 mg p.o. qd. x3 days (Not an FDA-approved 
indication) 
Suppressive Therapy 
Fluconazole 50 mg po 3x/week or 200 mg po Ix/week is under 
study . 
Podofilox or 25% podophyllin in tincture of benzoin applied 
topically (apply weekly x4) 
Alternatives: cryotherapy with liquid nitrogen, electocautery. 
Pap smears (q 6 months) 
Colposcopy with cervical biopsy if pap is abnormal. 
Outpatient (temp <38, WBC < 11 ,000, minimal evidence of 
peritonitis, active bowel sounds, qd p.o. intake) : 
a. Ceftriaxone 250 mg IM single dose plus doxycycline 100 mg 
bid po xl4 days 
b. Cefoxitin 2.0 gm IM single dose plus probenecid 1.0 gm. 
concurrently plus doxycycline 
c. Ofloxacin 400 mg po bid plus metronidazole (500 mg bid) or 
clindamycin (450 mg q6h) for 14 days . 
Hospitalized 
a. Cefoxitin 2.0 gm q 6h IV plus doxycycline 0.1 gm IV q 12 
hr. x min. 4 days and afebrile x48 hrs. 
b. Clindamycin 900 mg q. 8 hr. IV plus gentamicin (same time 
frame). Follow with oral agent doxycycline) to complete 
14 days. 
Mucocutaneous: 
Acyclovir 200 mg po 5x/day x IO days 
Suppression: 
Acyclovir 400 mg p.o . bid indefinitely . 
Summary of Clinical Situations and Recommendations for 
Use of Zidovudine (AZT) to Reduce Perinatal HIV Transmission 
Per U.S. Department of Health & Human Services. Recommendations of the U.S. Public Health Service Task Force on the use ofzidovudine to reduce perinatal transmis,ion 
of human immunodeficiency virus. Morbidity and Mortality Weekly Report 43 (RR-I) August 5, 1994. See Reverse Side for Protocol 
Clinical Situation 
Pregnant HIV-infected women with CD4+ T-
lymphocyte counts > or= to 200 who are at 
14 - 34 weeks of gestation and who have no 
clinical indications for ZDV and no history of 
extensive (>6 months) prior antiretroviral 
therapy. (This represents the group studied in 
ACTG Protocol 076) 
Pregnant HIV-infected women who are at >34 
weeks of gestation, who have no history of 
extensive (>6 months) prior antiretroviral 
therapy, and who do not require ZDV for 
their own health. 
Pregnant HIV-infected women with CD4+ T-
lymphocyte counts <200 who are at 14 - 34 
weeks of gestation, who have clinical 
indications for ZDV, and who have no history 
of extensive (>6 months) prior antiretroviral 
therapy. 
Pregnant HIV-infected women who have a 
history of extensive (>6 months) ZDV 
therapy and/or other antiretroviral therapy 
before pregnancy. 
Pregnant HIV-infected women who have not 
received antepartum antiretroviral therapy and 
who are in labor. 
Infants who are born to HIV-infected women 
who have received no intrapartum ZDV 
therapy. 
Recommendation (See Reverse Side for ACTG Protocol 076) 
The health care provider should recommend the full ACTG Protocol 076 
regimen to all HIV-infected pregnant women in this category. This 
recommendation should be presented to the pregnant woman in the 
context of a risk-benefit discussion : a reduced risk of transmission can 
be expected, but the long-term adverse consequences of the regimen are 
not known. The decision about this regimen should be made by the 
woman after discussion with her health care provider. 
The health care provider should recommend the full ACTG Protocol 076 
regimen in the context of a risk-benefit discussion with the pregnant 
woman. The woman should be informed that ZDV therapy may be less 
effective than that observed in the ACTG Protocol 076 , because the 
regimen is being initiated in the third trimester. 
The health care provider should recommend initiation of antenatal ZDV 
therapy to the woman for her own health benefit. The intrapartum and 
neonatal components of the ACTG Protocol 076 regimen should be 
recommended until further information becomes available. This 
recommendation should be presented in the context of a risk benefit 
discussion with the pregnant woman. 
Because data are insufficient to extrapolate the potential efficacy of the 
ACTG Protocol 076 regimen for this population of women, the health 
care provider should consider recommending the ACTG Protocol 076 
regimen on a case-by-case basis after a discussion of the risks and 
benefits with the pregnant woman . Issues to be discussed include her 
clinical and immunologic stability on ZDV therapy, the likelihood she is 
infected with a ZDV-resistant HIV strain and, if relevant, the reasons for 
her current use of an alternative antiretroviral agent (e.g., lack of 
response to or intolerance of ZDV therapy). Consultation with experts in 
HIV infection may be warranted. The health care provider should make 
the ACTG Protocol 076 regimen available to the woman. Although its 
effectiveness may vary depending on her clinical status. 
For women with HIV infection who are in labor and who have not 
received the antepartum regimen component of the ACTG Protocol 076 
regimen (either because of lack of prenatal care or because they did not 
wish to receive antepartum therapy), the health care provider should 
discuss the benefits and potential risks of the intrapartum and neonatal 
components of the ACTG Protocol 076 regimen and offer ZDV therapy 
when the clinical situation permits . 
If the clinical situation permits and if ZDV therapy can be initiated 
within 24 hours of birth, the health care provider should offer the ACTG 
Protocol 076 postpartum component of 6 weeks of neonatal ZDV 
therapy for the infant in the context of a risk-benefit discussion with the 
mother. Data from animal prophylaxis studies indicate that, if ZDV is 
administered, therapy should be initiated as soon as possible (within 
hours) after delivery. If therapy cannot begin until the infant is >24 
hours of age and the mother did not receive therapy during labor, no data 




I tested positive for HIV in April 
of 1992. I received the news one afternoon, 
when I was home alone . What I heard was 
a death sentence. I was going to die . I am 
a nurse and had a basic knowledge about 
HIV. That knowledge went right out the 
window and I lived in a world of pure 
emotions; mostly fear and panic . I never 
dreamed that I would really test positive , 
after all I only was tested to humor someone 
else. I wasn't aware of any other women 
who had HIV . I basically viewed it as a 
"gay mans disease''. I certainly couldn't tell 
anyone . I had seen and read the news 
stories about families who had been burned 
out of their houses and people who had lost 
their jobs, families and friends . What if that 
happened to me? What would people think? 
Does this mean that I am bad? Our society 
has placed an inordinate judgmental burden 
on people living with HIV. You have to 
have done something wrong to get this virus. 
If I had become infected because of a blood 
transfusion or as a consequence of being 
raped, then I am viewed as a poor innocent 
victim. However, if I acquired this virus as 
a result of unprotected sex or the use of IV 
drugs, then I am a "bad girl" , and the 
implication is that I deserved it. I've heard 
numerous stories from other women who 
were misdiagnosed or undiagnosed because 
their physician thought that they couldn't 
possibly have HIV - they were "nice girls". 
The burden and stress of living with 
such a huge secret finally outweighed my 
fears . I started to think about how I could 
disclose and to whom. I needed support. 
Could I get it and still protect myself, both 
physically and emotionally? I was lucky. I 
only lost my job and a few friends. I 
eventually decided to speak publicly . As a 
result I receive anonymous phone calls and 
letters telling me to move out of my 
neighborhood; they don't want "my kind" 
here. 
It was very difficult for me to look to the 
various AIDS service organizations for help 
and support. I viewed them as being places 
that were set up for men and was very 
suspicious of their ability to be open to 
dealing with a woman. I eventually joined 
a support group for women and over time 
met about IO other women from my area. 
My support group became very important to 
me. It is a group of women who have 
experienced loss and yet still have hope. 
Many of them have been in this place before 
me and are able to tolerate my restlessness, 
my terror, my despair, my rage . It is a place 
where I can experience feelings that would 
be burdensome for others. Yet it is a double 
edged sword; for each person that I meet 
who can understand and support me is also 
someone whom I may watch get sick and 
die . And that's happened many times. 
There are many more women, (over 40), 
who live in my area that are HIV positive , 
who live in fear and are unable to go to a 
support group. Many do not feel safe 
enough to receive AIDS related mail or 
newsletters at their homes. They are afraid 
for their jobs, that their children may be 
ostracized, that their families will place 
blame, or for their physical safety. Having 
lived with my own secret for a limited 
period of time , I know how difficult that is. 
Because I am an information 
oriented person and have access to a medical 
center library, I am constantly looking for 
information on Women and HIV. At first , I 
didn't find much. Most of the medical 
information was based on studies that were 
done on men. Women seemed to be either 
ignored or viewed as vessels or vectors of 
this virus. If it was acknowledged that 
women got HIV, why weren't there any 
studies about women? There was 
information about women transmitting it to 
their babies, but very little about women 
themselves. All of the drug studies were 
done on men. How does anyone know how 
my hormone levels may or may not react 
with these drugs. Does the different fat 
content of my body have any effect? Is my 
reproductive system affected by HIV? If so , 
how? It scares me and makes me very 
angry about how little is known. It wasn't 
until last year that the first large natural 
history study was started on women and the 
CDC changed it's definition of AIDS to 
include a women specific indicator. The 
uncertainty of living with this virus is like 
carrying a 20 lb bag of garbage on your 
shoulder and not knowing when it's going to 
break. I have enough to think about and to 
deal with, without wondering or worrying 
what's different about me because I'm a 
woman. 
The decision to find regular medical 
care was huge. Everyone makes mistakes 
and no one knows everything: secretaries 
make typos, businesses make bad 
investments - but this is my life. Would I 
die an early death because I was not 
competent enough to discern and judge the 
incompetency of my doctor? It was over 6 
months after my diagnosis before I went to 
a doctor, (after I finally found one who 
knew something about HIV and who would 
see me) . My primary physician is my 
consultant. I respect his opinion and 
judgement and usually do take his advice to 
heart, but in the end it's my body ; I have to 
"run the show". However I find myself in 
the position of having to educate other 
physicians. I resent the fact that I need to 
remind my GYN physician that I need to see 
her every 6 months for a pap smear or that 
she assumes because of my HIV status that 
I'm not sexually active and don't need birth 
control. It's not my job to stay informed 
enough so that I can inform her. I'm lucky 
because I have access to information that 
most women don't so that I can stay 
informed; and I have the skills to speak up, 
to question, and to talk back. 
What do I need from a physician? I need 
your educated professional advice , not your 
personal judgments. What I need is personal 
medical care , not just medicine. 
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9:00am - 4:00fu,t, at 
(&'00)&'71-2701. 
World AIDS Cases 2,500,000* 
us AIDS Cases 361,509 HIV & Women in the U.S. 
us AIDS Deaths 220,871 AIDS: 36,690 HIV : 80,000-
140,000 Total US cases and deaths reported through 
12/31/93 Median Age for AIDS: 30-34 
Percentage of U.S. AIDS Cases: 15% 
Maine AIDS Cases 530 
Maine AIDS Deaths 279 
Total Maine cases and deaths reported through 06/30/94 
*Estimated 
Educational Sessions 
October 16, 1994 
October 19-21, 1994 
October 24, 1994 
October 26, 1994 
October 27, 1994 
November l, 1994 
November 2, 1994 
November 14, 1994 
November 28, 1994 
November 30, 1994 
December 11 , I 994 
January 19, 1995 
February 15, 1995 
"Women's Health Care Issues Across the Life Span" Sponsored by USM at the Ramada Inn. Port. 
"CareandManagementoftheHIVIAIDSPatient:ACourseforPrimaryCareProuiders'Sponsored 
by the New England AIDS education and Training Center. University of Mass. Medical Center 
"HIV Disease - Nursing Implications" St. Josephs College 
"Primary Care Management of HIV" Univ. of Me. Orono 
"HIV Update" Wentworth Douglas Hospital, Dover, N.H. 
""Yokohama Update" Mercy Hospital - ANAC Meeting 
"Community, Advocacy, & Family Connections: Contemporary Practice with HIV/AIDS' 
Sponsored by USM & ACS at the Holiday Inn by the Bay, Portland. 
"HIV Update" PenBay Medical Center, Rockport Me. 
"Psychosocial Issues & HIV" at University of New England 
"HIV Update" The AIDS Project, Portland, Maine 
"Women and HIV" location TBA, Bangor Maine 
"Outpatient Management of HIV" Grand Rounds, Mid Maine Medical Ctr. Waterville.Me. 
"Outpatient Management of HIV" Grand Rounds, Franklin Mem. Hosp., Farmington. Me. 
For more information regarding the above educational sessions, please call the ACS at 871-2099. 
If you are providing an HIV/AIDS related Educational Session, please let us know at (800)871-2701. 
Maine Medical Center 
AIDS Consultation Service 
22 Bramhall Street 
Portland Maine 04102 
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